clinical trial Archives | Page 2 of 5 | Be Korea-savvy
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

SHANGHAI, China, and REDWOOD CITY, Calif., Aug. 18 (Korea Bizwire) —  Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or [...]

Patients Rate their Clinical Trial Experience Positively, but Trial Locations Still Pose Barriers to Enrollment

Patients Rate their Clinical Trial Experience Positively, but Trial Locations Still Pose Barriers to Enrollment

NEW YORK, July 27 (Korea Bizwire) – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, released its first “Patient Perspectives on Clinical Trial Participation” report, which measured patient attitudes in relation to all stages of the clinical trial process following the onset of the COVID-19 pandemic. The study, conducted online in partnership [...]

Informa Pharma Intelligence Launches Citeline Study Feasibility to Accelerate Clinical Trial Timelines

Informa Pharma Intelligence Launches Citeline Study Feasibility to Accelerate Clinical Trial Timelines

NEW YORK, June 16 (Korea Bizwire) – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, today announced the launch of Citeline Study Feasibility – an AI-driven platform that delivers predictive analytics to improve clinical trial decisions and cycle times. By combining its best-in-class data sets with machine learning capabilities, this solution will [...]

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

BARCELONA, Spain, May 6 (Korea Bizwire) — Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase [...]

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

EDMONTON, Alberta, April 21 (Korea Bizwire) — Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant TriAl with LEE), has enrolled 5101 patients globally. [...]

Novadiscovery Announces Key Collaboration with Janssen France to Provide in Silico Based Decision Support for Clinical Development

Novadiscovery Announces Key Collaboration with Janssen France to Provide in Silico Based Decision Support for Clinical Development

Lyon, France, Dec. 17 (Korea Bizwire) – Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jinkō®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed [...]

Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)

Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)

La Chaux-de-Fonds, Switzerland, Sept. 24 (Korea Bizwire) — Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the company’s novel next generation dual PI3K δ/γ inhibitor, in the journal Cancers.   — Single-agent Tenalisib was well tolerated with a good overall response rate (ORR) in both peripheral and cutaneous T-cell [...]

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

VANCOUVER, British Columbia, Aug. 5 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The countries participating in [...]

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate

GAITHERSBURG, Md., Aug. 4 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID‑19 vaccine with and without Matrix‑M™ adjuvant in healthy adults 18-59 years of age. NVX‑CoV2373, the Company’s recombinant [...]

S. Korea Approves Phase 1 Trials for Celltrion’s COVID-19 Treatment Substance

S. Korea Approves Phase 1 Trials for Celltrion’s COVID-19 Treatment Substance

SEOUL, July 17 (Korea Bizwire) — South Korea approved phase one clinical trials for Celltrion Inc.’s coronavirus antibody treatment substance, the country’s drug safety agency said Friday. The move to test CT-P59 marks the first time that a locally made genetic recombination antibody treatment material has been given the green light to be used on [...]